September 6, 2012 – CANCELLED due to Lufthansa strike. Seminar will now take place on 15th November 2012!
5 PM in Mainz, Germany
TRON – Building 708 at University Medical Center Mainz
Prof. Dr. Michel Aguet
National Center of Competence in Research (NCCR) “Molecular Oncology”, Lausanne, Switzerland
“Role of BCL9 proteins in Wnt-mediated stem cell maintenance”
Prof. Aguet is the director of the National Centre of Competence in Research (NCCR) in Lausanne. Working with partners from different university hospitals and the pharmaceutical industry, the NCCR seeks new cancer therapies, discover mechanisms of tumor formation and endeavor to translate these findings into therapeutic approaches. The research projects target different aspects of the fundamental biology of tumors and the response of healthy cells to cancer.
Prof. Michel Aguet received his MD in Zürich in 1974. He carried out a postdoctoral fellowship with Dr. Ion Gresser in Villejuif, France, and moved back to the University of Zürich, where he became group leader at the Institute of Virology (Director Prof. Jean Lindenmann), and, in 1989, Associate Professor at the Institute of Molecular Biology (Director Prof. Charles Weissmann). During this time period his research focused largely on the molecular biology of interferons (cloning of the interferon gamma receptor, generation of various interferon signaling mutants in the mouse). He established a gene targeting platform which was used collaboratively to generate mice that lack the prion related protein PrP. In 1994 he moved to Genentech Inc., South San Francisco, to head the Molecular Biology Department and supervise oncology research ranging from signaling pathways in cell growth and differentiation to technology development, including notably antibody based approaches and conditional gene regulation strategies in the mouse. In 1996 he was appointed Director of ISREC. His current research interests are in the area of cancer related developmental signaling pathways, with a focus on the identification and validation of novel therapeutic targets. In 2000 he became the director of the National Center of Competence in Research (NCCR) in Molecular Oncology, a national program launched by the Swiss National Science Foundation to encourage more clinically oriented cancer research and for which ISREC is the leading house.